| 1. |
- Kanai, M, et al.
(författare)
-
- 2023
-
swepub:Mat__t
|
|
| 2. |
- Turtelboom,, et al.
(författare)
-
The TESS-Keck Survey. XI. Mass Measurements for Four Transiting Sub-Neptunes Orbiting K Dwarf TOI-1246
- 2022
-
Ingår i: Astronomical Journal. - : American Astronomical Society. - 1538-3881 .- 0004-6256. ; 163:6
-
Tidskriftsartikel (refereegranskat)abstract
- Multiplanet systems are valuable arenas for investigating exoplanet architectures and comparing planetary siblings. TOI-1246 is one such system, with a moderately bright K dwarf (V = 11.6, K = 9.9) and four transiting sub-Neptunes identified by TESS with orbital periods of 4.31, 5.90, 18.66, and 37.92 days. We collected 130 radial velocity observations with Keck/HIRES and TNG/HARPS-N to measure planet masses. We refit the 14 sectors of TESS photometry to refine planet radii (2.97 +/- 0.06 R (circle plus), 2.47 +/- 0.08 R (circle plus), 3.46 +/- 0.09 R (circle plus), and 3.72 +/- 0.16 R (circle plus)) and confirm the four planets. We find that TOI-1246 e is substantially more massive than the three inner planets (8.1 +/- 1.1 M (circle plus), 8.8 +/- 1.2 M (circle plus), 5.3 +/- 1.7 M (circle plus), and 14.8 +/- 2.3 M (circle plus)). The two outer planets, TOI-1246 d and TOI-1246 e, lie near to the 2:1 resonance (P (e)/P ( d ) = 2.03) and exhibit transit-timing variations. TOI-1246 is one of the brightest four-planet systems, making it amenable for continued observations. It is one of only five systems with measured masses and radii for all four transiting planets. The planet densities range from 0.70 +/- 0.24 to 3.21 +/- 0.44 g cm(-3), implying a range of bulk and atmospheric compositions. We also report a fifth planet candidate found in the RV data with a minimum mass of 25.6 +/- 3.6 M (circle plus). This planet candidate is exterior to TOI-1246 e, with a candidate period of 93.8 days, and we discuss the implications if it is confirmed to be planetary in nature.
|
|
| 3. |
- Barlow, Sue, et al.
(författare)
-
Scientific report of the Endocrine Active Substances Task Force
- 2010
-
Ingår i: EFSA Journal. - Parma, Italy : European Food Safety Authority. - 1831-4732. ; 8:11
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Discussions within the Scientific Committee and the Advisory Forum have called for the development of a common approach within EFSA towards endocrine active substances. The aim of this report by an internal EFSA task force is to clarify the state-of-play, and provide recommendations for scientific and communication issues. Both specific issues and new regulations make it necessary to follow up on recent developments with the EU bodies, Member States, and internationally, in order to avoid diverging assessment approaches and the duplication of work. The proposed actions for EFSA are to contribute to the work in progress under the auspices of DG Environment and to continue its participation in the ongoing OECD activities in the area of testing of chemicals. The development of a generally accepted risk assessment methodology is an additional challenge due to the complexity of the issues involved. Here, the task force recommends that EFSA continues its activities aimed at developing harmonised methodologies for risk assessment of combined exposures to endocrine active substances in food. EFSA should continue to build a dialogue to develop a common strategy with the EC, other EU bodies, Member States’ Competent Authorities, international organisations and partners, as well as external experts and stakeholders on the before mentioned issues. In line with these recommendations, it is proposed that EFSA creates a working group of Panel experts and national experts to advise on prioritising the work on endocrine active substances. EFSA should also work with the experts in its Advisory Group on Risk Communications in conjunction with the communication experts from Member States, and continues to monitor and analyse media and stakeholder developments, in order to define a strategy for communications addressing both the collective group and specific endocrine active substances.
|
|
| 4. |
- Kirkeby, Agnete, et al.
(författare)
-
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD
- 2023
-
Ingår i: Cell Stem Cell. - 1934-5909. ; 30:10, s. 1299-1314
-
Tidskriftsartikel (refereegranskat)abstract
- Cell replacement therapies for Parkinson's disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting the first-in-human STEM-PD phase I/IIa clinical trial along with the trial design. The STEM-PD product was manufactured under GMP and quality tested in vitro and in vivo to meet regulatory requirements. Importantly, no adverse effects were observed upon testing of the product in a 39-week rat GLP safety study for toxicity, tumorigenicity, and biodistribution, and a non-GLP efficacy study confirmed that the transplanted cells mediated full functional recovery in a pre-clinical rat model of PD. We further observed highly comparable efficacy results between two different GMP batches, verifying that the product can be serially manufactured. A fully in vivo-tested batch of STEM-PD is now being used in a clinical trial of 8 patients with moderate PD, initiated in 2022.
|
|
| 5. |
- Sumaila, U. Rashid, et al.
(författare)
-
WTO must ban harmful fisheries subsidies
- 2021
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 374:6567, s. 544-544
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
